This is a working overview of RP-HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
The copper-binding activity of this sequence was described in the 1970s during studies of liver tissue and plasma factors. Early work identified the peptide as a component that influenced copper uptake by cells and that appeared in wound fluid. Later investigations examined its presence across species, reporting the same chain in human and animal samples. A decline in measured concentration with age became a recurring observation, although the underlying causes remain incompletely characterised.
Published studies describe the complex in several research contexts, including collagen synthesis, antioxidant behaviour, and wound repair models. Much of this work is conducted in cultured cells or in small animal systems, and the findings are frequently cited in reviews of copper peptides. Direct clinical evidence in humans is comparatively limited, and reported outcomes vary with formulation and study design. Whether free chain or metal-bound form was used is not always stated, a point that complicates comparison between reports.
GHK-Cu is a coordination complex formed between the peptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The unbound chain, abbreviated GHK, consists of three amino acids and occurs naturally in human plasma, saliva, and urine. Binding of the metal is mediated mainly by the imidazole nitrogen of the histidine residue together with backbone amides, producing a stable chelate. Ingredient nomenclature often lists the same substance as copper tripeptide-1. Its charge and solubility behaviour differ from those of the metal-free chain.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry to confirm the expected mass. Copper content is measured separately by inductively coupled plasma optical emission spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not establish the metal-to-peptide ratio. Visible spectroscopy provides a rapid check on complex integrity through the absorption band in the visible region. Agreement between the peptide assay and the copper assay is the practical test of whether a sample is the intended complex rather than a mixture.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II) peptide complex | Coordination compound rather than a simple salt |
| Peptide sequence | Glycyl-L-histidyl-L-lysine | Abbreviated GHK in most literature |
| Molecular formula | C14H22N6O4Cu | Reported for the 1:1 complex |
| Principal binding site | Histidine imidazole nitrogen | Backbone amides contribute additional coordination |
| Common synonym | Copper tripeptide-1 | Used in ingredient and product labelling |
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
Material described as GHK-Cu appears in several distinct markets, including cosmetic ingredients, laboratory reagents, and consumer products, and the quality expectations attached to each differ. A certificate of analysis generally reports peptide purity by chromatography, copper content, appearance, and residual solvents or counterions. Counterion identity matters, because the complex is usually supplied as an acetate or a similar salt, and the counterion contributes to the measured mass. Independent verification of sequence and metal stoichiometry is advisable when a material is used for quantitative work. Batch-to-batch variation is common and should be documented rather than assumed negligible.
Copper peptide solutions tend to resist degradation better than many free peptides, because the bound metal protects the N-terminus and reduces susceptibility to some peptidases. Backbone hydrolysis, oxidation of the histidine imidazole ring, and photochemical reactions remain the principal degradation routes. Aqueous solutions are generally most stable near neutral to mildly acidic pH, while strongly alkaline conditions accelerate hydrolysis. Light exposure is usually avoided, since both the peptide and the copper center can take part in photochemical processes. Stability data published by suppliers often describe short-term behavior rather than multi-year shelf life.
Mechanistic accounts focus on how the complex delivers copper and how the released peptide interacts with the extracellular matrix. Copper is an essential cofactor for lysyl oxidase and other enzymes involved in collagen and elastin cross-linking, and GHK is one of several peptides able to carry the metal. Reported effects include altered gene expression in fibroblasts and changes in matrix metalloproteinase activity, although many of these findings come from cell culture rather than whole organisms. The relative contribution of the peptide backbone, the copper ion, and downstream copper metabolism is not fully resolved.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-lysine and a copper(II) ion. The peptide sequence is conventionally written as Gly-His-Lys, abbreviated GHK. Copper binds through the imidazole nitrogen of histidine, the alpha-amino group, and a deprotonated amide nitrogen, producing a square-planar geometry. The complex carries a net positive charge near physiological pH and is intensely blue in aqueous solution. The metal-free peptide is often written simply as GHK, while the copper-bound form is written GHK-Cu.
Uranium-238 is predominantly an alpha emitter, decaying to thorium-234. It ultimately decays through the uranium series, which has 18 members, into lead-206. Uranium-238 is not fissile, but is a fertile isotope, because after neutron activation it can be converted to plutonium-239, another fissile isotope. Indeed, the 238U nucleus can absorb one neutron to produce the radioactive isotope uranium-239. 239U decays by beta emission to neptunium-239, also a beta-emitter, that decays in its turn, within a few days into plutonium-239. 239Pu was used as fissile material in the first atomic bomb detonated in the "Trinity test" on 16 July 1945 in New Mexico. Uranium-235 has a half-life of about 7.04×108 years; it is the next most stable uranium isotope after 238U and is also predominantly an alpha emitter, decaying to thorium-231. Uranium-235 is important for both nuclear reactors and nuclear weapons, because it is the only uranium isotope existing in nature on Earth in significant amounts that is fissile. This means that it can be split into two or three fragments (fission products) by thermal neutrons. The decay chain of 235U, which is called the actinium series, has 15 members and eventually decays into lead-207. The constant rates of decay in these decay series makes the comparison of the ratios of parent to daughter elements useful in radiometric dating. Uranium-236 has a half-life of 2.342×107 years and is not found in significant quantities in nature.
However, because CPE is not a rate-limiting enzyme for the production of most neuropeptides and peptide hormones, it is not clear how relatively modest decreases in CPE activity can cause physiological effects.
All work in Berlin ceased by July. Hahn and his family moved to the house of a textile manufacturer there. Life became precarious for those married to Jewish women. One was Philipp Hoernes, a chemist working for Auergesellschaft, the firm that mined the uranium ore used by the project. After the firm let him go in 1944, Hoernes faced being conscripted for forced labour. At the age of 60, it was doubtful that he would survive. Hahn and Nikolaus Riehl arranged for Hoernes to work at the KWIC, claiming that his work was essential to the uranium project and that uranium was highly toxic, making it hard to find people to work with it. Hahn was aware that uranium ore was fairly safe in the laboratory and could be mined safely using the correct equipment and procedures, but the 2,000 female slave labourers from the Sachsenhausen concentration camp who mined it in Oranienburg suffered agonising deaths because their Nazi slavedrivers wilfully neglected their safety. Another physicist with a Jewish wife was Heinrich Rausch von Traubenberg. Hahn certified that his work was important to the war effort, and that his wife Maria, who had a doctorate in physics, was required as his assistant. After he died on 19 September 1944, Maria faced being sent to a concentration camp. Hahn mounted a lobbying campaign to get her released, but to no avail, and she was sent to the Theresienstadt Ghetto in January 1945. She survived the war, and was reunited with her daughters in England.
Flaps may include skin in their construction. Skin is important for many reasons, but its role in thermoregulation, immune function, and blood supply aid in flap survival. The skin can be divided into three main layers: the epidermis, dermis, and subcutaneous tissue. Blood is mainly supplied to the skin by two networks of blood vessels. The deep network lies between the dermis and the subcutaneous tissue, while the shallow network lies within the papillary layer of the dermis. The epidermis is supplied by diffusion from this shallow network and both networks are supplied by collaterals, and by perforating arteries that bring blood from deeper layers either between muscles (septocutaneous perforators) or through muscles (musculocutaneous perforators). This robust and redundant blood supply is important in flap surgery, because flaps are cut off from other blood vessels when they are raised and removed from surrounding native tissue. The remaining blood supply must then keep the tissue alive until additional blood supply can be formed through angiogenesis.
== External links == Clinical trial number (NCT05656027 for "Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia (CLARITY)" at ClinicalTrials.gov Clinical trial number (NCT05728944 for "Phase 3 Efficacy Study of LNZ101 for the Treatment of Presbyopia (CLARITY)" at ClinicalTrials.gov Clinical trial number (NCT05753189 for "Phase 3 Safety Study for the Treatment of Presbyopia Subjects" at ClinicalTrials.gov
Sources: en.wikipedia.org
In 2005, ten countries accounted for the majority of the world's concentrated uranium oxides: Canada (27.9%), Australia (22.8%), Kazakhstan (10.5%), Russia (8.0%), Namibia (7.5%), Niger (7.4%), Uzbekistan (5.5%), the United States (2.5%), Argentina (2.1%) and Ukraine (1.9%). In 2008, Kazakhstan was forecast to increase production and become the world's largest supplier of uranium by 2009; Kazakhstan has dominated the world's uranium market since 2010. In 2021, its share was 45.1%, followed by Namibia (11.9%), Canada (9.7%), Australia (8.7%), Uzbekistan (7.2%), Niger (4.7%), Russia (5.5%), China (3.9%), India (1.3%), Ukraine (0.9%), and South Africa (0.8%), with a world total production of 48,332 tonnes. Most uranium was produced not by conventional underground mining of ores (29% of production), but by in-situ leaching (66%). In the late 1960s, UN geologists discovered major uranium deposits and other rare mineral reserves in Somalia. The find was the largest of its kind, with industry experts estimating the deposits at over 25% of the world's then known uranium reserves of 800,000 tons. The ultimate available supply is believed to be sufficient for at least the next 85 years, though some studies indicate underinvestment in the late twentieth century may produce supply problems in the 21st century. Uranium deposits seem to be log-normal distributed. There is a 300-fold increase in the amount of uranium recoverable for each tenfold decrease in ore grade. In other words, there is little high grade ore and proportionately much more low grade ore available.
Gender incongruence is marked and sustained Patient meets diagnostic criteria for gender incongruence prior to gender-affirming hormone treatment in regions where a diagnosis is necessary to access health care Patient has capacity to consent to hormone therapy treatment Other possible causes of apparent gender incongruence have been identified and excluded Mental health and physical conditions that could negatively impact the outcome of treatment have been assessed Understands the effect of gender-affirming hormone treatment on reproduction and they have explored reproductive options The WPATH standards of care distinguish between gender-affirming hormone therapy, and hormone replacement therapy, with the latter referring to the replacement of endogenous hormones after a gonadectomy to prevent cardiovascular and musculoskeletal issues.
and an honorary citizen of the cities of Frankfurt am Main and Göttingen in 1959, and of Berlin (1968). Hahn was made an Officer of the Ordre National de la Légion d'Honneur of France (1959), and was awarded the Grand Cross First Class of the Order of Merit of the Federal Republic of Germany (1959). In 1966, US President Lyndon B. Johnson and the United States Atomic Energy Commission (AEC) awarded Hahn, Lise Meitner and Fritz Strassmann the Enrico Fermi Award. The diploma for Hahn bore the words: "For pioneering research in the naturally occurring radioactivities and extensive experimental studies culminating in the discovery of fission." He received honorary doctorates from the University of Gottingen, the Technische Universität Darmstadt, the Goethe University Frankfurt in 1949, and the University of Cambridge in 1957. Objects named after Hahn include:
==== Esterification ==== HA can be reacted with an epoxide such as glycidyl methacrylate and triethylamine in water to form these ester bonds. Alkyl halides, tosylates, and diazomethane can also be used to create ester bonds, but this reaction requires you to convert the native HA sodium salt to its TBA salt, which can be time consuming. These esterification reactions at the carboxyl group usually require a low pH. There are many different types of esterification reactions at both the carboxyl and hydroxyl groups.
Sources: en.wikipedia.org
GHK denotes the unbound chain of three amino acids. GHK-Cu describes the form in which a copper(II) ion is held by that chain. The two are not interchangeable in solution, since charge, molecular weight, and reactivity differ.
The chain occurs in human plasma, saliva, and urine. Measured amounts are reported to fall with age. Copper binding by the sequence is treated as part of normal metal handling in tissue.
The bound copper(II) centre contributes to redox behaviour and to stability under physiological conditions. Free copper ions can participate in reactions that generate reactive species, while chelated metal is generally more controlled. The chain may also serve as a carrier for copper in experimental systems.
Dry powder is best kept cold, dark and sealed, typically at -20 °C for long-term storage or 2 to 8 °C for material in regular use. Vials should be warmed to room temperature before opening to prevent moisture condensing on the contents. Aqueous stock solutions degrade faster and are usually prepared fresh.